A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Latest Information Update: 02 Jun 2024
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms POETYK PsA-1
- Sponsors Bristol-Myers Squibb
- 21 May 2024 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2022 Planned End Date changed from 13 Oct 2026 to 12 May 2027.
- 14 Nov 2022 Planned primary completion date changed from 16 Jan 2024 to 3 Sep 2024.